WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206081
Description: Ulodesine, also known as BCX4208, is a purine nucleoside phosphorylase (PNP) inhibitor in development as a once-daily oral, chronic treatment for gout. Ulodesine is currently being developed by Biocryst. Ulodesine acts upstream of xanthine oxidase in the purine metabolism pathway to reduce the production of serum uric acid (sUA). Ulodesine has an IC(50) of 0.5 nM to PNP. BCX-4208 is currently undergoing early clinical investigation in psoriasis and gout.
MedKoo Cat#: 206081
Chemical Formula: C12H16N4O3
Exact Mass: 264.12224
Molecular Weight: 264.28
Elemental Analysis: C, 54.54; H, 6.10; N, 21.20; O, 18.16
Ulodesine is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: BCX4208, BCX 4208, BCX-4208, Ulodesine, DADMe-immucillin H
IUPAC/Chemical Name: 7-(((3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one
InChi Key: AFNHHLILYQEHKK-BDAKNGLRSA-N
InChi Code: InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
SMILES Code: O=C1C(NC=C2CN3C[C@H](O)[C@@H](CO)C3)=C2N=CN1
The following data is based on the product molecular weight 264.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, Morris P, Chand P, Babu YS. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol. 2010 Jul;10(7):784-90. doi: 10.1016/j.intimp.2010.04.009. Epub 2010 Apr 22. PubMed PMID: 20399911.
2: Kamath VP, Juarez-Brambila JJ, Morris PE Jr. Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. doi: 10.1002/dta.24. PubMed PMID: 20355185.